MGO One Seven LLC Acquires 36,045 Shares of Pfizer Inc. $PFE

MGO One Seven LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 33.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 143,176 shares of the biopharmaceutical company’s stock after purchasing an additional 36,045 shares during the quarter. MGO One Seven LLC’s holdings in Pfizer were worth $3,565,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Premier Fund Managers Ltd bought a new position in Pfizer during the fourth quarter valued at about $10,917,000. Sequoia Financial Advisors LLC raised its position in Pfizer by 1.0% in the fourth quarter. Sequoia Financial Advisors LLC now owns 338,836 shares of the biopharmaceutical company’s stock worth $8,437,000 after acquiring an additional 3,498 shares during the period. WealthShield Partners LLC boosted its stake in Pfizer by 5.3% in the fourth quarter. WealthShield Partners LLC now owns 26,545 shares of the biopharmaceutical company’s stock valued at $711,000 after acquiring an additional 1,328 shares during the last quarter. Gateway Investment Advisers LLC boosted its stake in Pfizer by 13.8% in the fourth quarter. Gateway Investment Advisers LLC now owns 66,978 shares of the biopharmaceutical company’s stock valued at $1,668,000 after acquiring an additional 8,147 shares during the last quarter. Finally, K.J. Harrison & Partners Inc grew its position in shares of Pfizer by 82.8% during the 4th quarter. K.J. Harrison & Partners Inc now owns 119,503 shares of the biopharmaceutical company’s stock valued at $2,976,000 after acquiring an additional 54,140 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Scotiabank initiated a Buy view on Pfizer, adding to recent analyst confidence in the stock. Pfizer (PFE) Receives a Buy from Scotiabank
• Positive Sentiment: Erste Group slightly raised its FY2026 EPS estimate for Pfizer, reinforcing expectations that earnings remain stable and in line with consensus.
• Positive Sentiment: Recent coverage highlighted Pfizer’s Q1 beat, better-than-expected sales, and progress in its oncology pipeline, suggesting the company’s newer drugs are becoming more important to the investment story. How Pfizer’s Q1 Beat, Oncology Wins and Patent Deals At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer’s dividend remains a major draw for income investors, and a recent article argued that the high yield is still supported by management’s execution and cash flow. Pfizer’s 6.5% Dividend Yield Looked Too Good to Be True — but Management Just Silenced the Skeptics
• Neutral Sentiment: Pfizer is continuing to advance a new Phase 1 cancer trial, which signals ongoing investment in oncology but is still too early to materially change near-term financial results. Pfizer’s New Phase 1 Cancer Trial Signals Fresh Oncology Push for PFE Investors
• Neutral Sentiment: Pfizer was also mentioned in a cancer-care industry recognition announcement, but the item is mostly reputational and unlikely to move the stock on its own.
• Negative Sentiment: Pfizer halted an early-stage cancer study, and investors may view the termination as a small setback for its oncology pipeline, even if the financial impact is limited. Pfizer Terminates Early-Stage Cancer Trial: What It Means for PFE Investors
• Negative Sentiment: Pfizer ended another early-stage lymphoma combination trial, which adds to concerns that some pipeline programs may not advance as hoped. Pfizer Ends Early-Stage Lymphoma Combo Trial, Trimming a Small Piece of Its Oncology Upside

Pfizer Stock Down 3.1%

PFE opened at $25.65 on Friday. Pfizer Inc. has a 12 month low of $21.97 and a 12 month high of $28.75. The company has a market cap of $146.17 billion, a PE ratio of 19.58 and a beta of 0.35. The company has a current ratio of 1.25, a quick ratio of 0.87 and a debt-to-equity ratio of 0.67. The company has a 50 day moving average of $27.14 and a 200 day moving average of $26.16.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s payout ratio is presently 131.30%.

Wall Street Analysts Forecast Growth

PFE has been the subject of several research analyst reports. CICC Research began coverage on shares of Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 price target for the company. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Wednesday, February 4th. UBS Group raised their target price on Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research report on Monday, April 13th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday. Finally, Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $28.74.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.